Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Type
Type
Guidance (86)
Guidance programme
Guidance programme
HealthTech guidance (2)
Technology appraisal guidance (84)
Apply filters
Showing 71 to 80 of 86
Keyword or reference number: cancer
`Remove $Keyword or reference number: cancer filter`
Guidance and quality standards awaiting development
Title
Type
Technologies to improve detection of endometrial
cancer
HealthTech guidance
Technology for
cancer
case finding using primary care records
HealthTech guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung
cancer
untreated with checkpoint inhibitors [TSID12064]
Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung
cancer
[ID6708]
Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell
cancer
[ID5077]
Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung
cancer
[ID6158]
Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell
cancer
after platinum-based chemotherapy (review of TA1068) [ID6682]
Technology appraisal guidance
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast
cancer
after neoadjuvant chemotherapy [ID6509]
Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast
cancer
[ID6620]
Technology appraisal guidance
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung
cancer
[ID6603]
Technology appraisal guidance
Previous page
1
…
6
7
Current page
8
9
Page
8
of
9
Next page
Results per page
10
25
50
All
Back to top